CHARACTERISTICS OF USERS OF VILDAGLIPTIN DISPENSED IN PHARMACIES OF PRIMARY HEALTH CARE ESTABLISHMENTS
Authors
-
Pamela Santibañez Saavedra
Servico de Salud de Los Ríos
https://orcid.org/0000-0002-1386-7717
Abstract
Introduction: the specific health guarantees regime guarantees access to treatments for type 2 diabetes mellitus, including metformin, glibenclamide and/or insulin. However, based on recent studies and the national clinical practice guideline, vildagliptin is recommended as first-line treatment for patients aged 65 years and older or those intolerant to metformin. The objective was to characterize the population using vildagliptin in primary health care facilities in the Los Ríos Region, comparing it with the profile recommended by the national clinical practice guidelines for the pharmacological treatment of type 2 diabetes mellitus. Methods: retrospective, observational, quantitative study. An anonymous database of the vildagliptin dispensing computer system of 359 users was reviewed and variables such as gender, age, origin, diagnosis and stage of chronic kidney disease were evaluated. In addition, the results of administrative audits were analyzed, focused on the control of patients using the drug. Results: a higher proportion of female users was observed (61.8%), 57.4% corresponded to the commune of Río Bueno, and the main age range was between 65 and 79 years (26.2%). Of the total, 231 users were diagnosed with type 2 diabetes mellitus, 39 of them had chronic kidney disease at some stage and 49 met the criteria recommended in the clinical practice guidelines. Conclusions: there was evidence of poor application of the recommendations of the clinical practice guidelines in the dispensing of vildagliptin; improvements should focus on the processes of prescribing and monitoring the use of the drug.
Keywords:
practice, Primary Health Care, vildagliptin, dipeptidyl peptidase 4, diabetes mellitus type 2References
Orozco Beltrán D. Nuevas opciones farmacológicas para el tratamiento de la diabetes tipo 2. Rev Clin Med Fam [Internet]. 2018 [citado 2024 Nov 20];11(3):122-4. Disponible en: https://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1699-695X2018000300122
Ministerio de Salud de Chile. Guía Práctica Clínica Tratamiento Farmacológico de la Diabetes Mellitus tipo 2, 2016-2017 Disponible en: http://www.repositoriodigital.minsal.cl/handle/2015/861
Hernández González K, Navarro Aparicio L. Beneficios de los inhibidores de la dipeptidil peptidasa-4 frente a otros hipoglucemiantes orales. Rev Med [Internet]. 2022;17(51):[. ISSN: 2007-1655. Disponible en: https://portal.amelica.org/ameli/journal/486/4863439004/html/
Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes, obesity & metabolism, 2016; 18(3):203–216, https://doi.org/10.1111/dom.1259.
Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Efecto de la sitagliptina en los resultados cardiovasculares en la diabetes tipo 2. N Engl J Med. 2015; 373:232-42. DOI:10.1056/NEJMoa1501352 Disponible en: https://pubmed.ncbi.nlm.nih.gov/26052984/
Karagiannis T, Boura P, Tsapas A. Safety of dipeptidyl peptidase 4 inhibitors: a perspective review. Ther Adv Drug Saf. 2014;5(3):138-146. DOI:10.1177/2042098614523031 Disponible en. https://pubmed.ncbi.nlm.nih.gov/25083269/
Mathur V, Alam O, Siddiqui N, et al. Insight into Structure Activity Relationship of DPP-4 Inhibitors for Development of Antidiabetic Agents. Molecules. 2023;28(15):5860. Published 2023 Aug 3. doi:10.3390/molecules28155860 Disponible en: https://pubmed.ncbi.nlm.nih.gov/37570832/
Godoy JG, Gutiérrez V, Montecinos M, Yenes A. Evaluación del perfil de eficacia y seguridad de vildagliptina en vida real de pacientes chilenos con diabetes mellitus tipo 2. Rev. méd. Chile [Internet]. 2015 Ene [citado 2024 Dic 26]; 143(1): 63-68. Disponible en: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872015000100008&lng=es. http://dx.doi.org/10.4067/S0034-98872015000100008.
Kalra S, Zargar AH, Sridhar GR, et al. Expert eValuation of Efficacy and Rationality of Vildagliptin "EVER-Vilda": An Indian Perspective. Clin Med Insights Endocrinol Diabetes. 2024;17. DOI: 10.1177/11795514231203911 Disponible en: https://pubmed.ncbi.nlm.nih.gov/38405679/
Forero, V. H., G. G. Ribón Quintero, y J. Echeverry-Raad. Vildagliptina en Pacientes diabéticos Tipo 2 con Riesgo Cardiovascular O Compromiso Renal. Revisión De Literatura. Revista Cuarzo, vol. 24, n.º 1, agosto de 2018, pp. 28-45, DOI:10.26752/cuarzo.v24.n1.345. Disponible en: https://revistas.juanncorpas.edu.co/index.php/cuarzo/article/view/345
Carrera-Acosta Lourdes, Salvador-Salvador Stefany, Torre-Maraví Gloria Edith. Evaluación de la adherencia de Guías de Práctica Clínica en el Seguro Social del Perú. Rev. Cuerpo Med. HNAAA [Internet]. 2021 Dic [citado 2024 Dic 26] ; 14( 4 ): 430-431. Disponible en: http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S2227-
Schaefer R, Schmidt HA, Ravasi G, Mozalevskis A, Rewari BB, Lule F, et al. Adoption of guidelines on and use of oral pre-exposure prophylaxis: a global summary and forecasting study. Lancet HIV. 2021;8(8):e502–10. doi:10.1016/S2352-3018(21)00127-2 Disponible en: https://pubmed.ncbi.nlm.nih.gov/34265283/
Wang T, Tan J, Liu X, et al. Barriers and facilitators for implementing clinical practice guidelines in primary care: an overview of systematic reviews. BMJ Open. 2023;13: e062158. doi:10.1136/bmjopen-2022-062158 Disponible en: https://pubmed.ncbi.nlm.nih.gov/36609329/
Saluja K, Reddy KS, Wang Q, et al. Improving WHO’s understanding of WHO guideline uptake and use in Member States: a scoping review. Health Res Policy Syst. 2022; 20:98. doi:10.1186/s12961-022-00899-y Disponible en: https://pubmed.ncbi.nlm.nih.gov/36071468/
M. Turégano-Yedro M., Cinza-Sanjurjo S., Cubelos-Fernández C., Segura-Fragoso A., Sánchez-Sánchez B., Sánchez-Rodríguez R. et al. Análisis del grado de cumplimiento de las recomendaciones de las guías de práctica clínica para el diagnóstico y seguimiento de las complicaciones crónicas vasculares en la diabetes tipo 2 en atención primaria. Med Fam SEMERGEN. 2020;46(3). Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S113835931930437X
Poblano-Verástegui Ofelia, Vieyra-Romero Waldo I, Galván-García Ángel F, Fernández-Elorriaga María, Rodríguez-Martínez Antonia I, Saturno-Hernández Pedro J. Calidad y cumplimiento de guías de práctica clínica de enfermedades crónicas no transmisibles en el primer nivel. Salud pública Méx [revista en la Internet]. 2017 Abr [citado 2024 Dic 26] ; 59(2): 165-175. Disponible en: http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0036-36342017000200165&lng=es.
Díaz MS. Uso de inhibidores de la dipeptidil peptidasa 4 en pacientes con diabetes en situaciones especiales. Med Fam SEMERGEN. 2018;44(1). Disponible en: https://doi.org/10.1016/S1138-3593(18)30371-X
Bekiari E, Rizava C, Athanasiadou E, et al. Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes. Endocrine. 2016;52(3):458-480. doi:10.1007/s12020-015-0841-1 Disponible en: https://pubmed.ncbi.nlm.nih.gov/26714458/
